Regulatory News:
TheraVet (Paris:ALVET) (Brussels:ALVET) (ISIN:
BE0974387194 - ticker: ALVET), a pioneering biotechnology company
specialising in the management of osteoarticular diseases in pets,
presents its half-year operational update ending December 31,
2021.
Enrico Bastianelli, Chief Executive Officer of TheraVet,
commented: “The second half of the year has been very
structuring for TheraVet. Our latest developments bring us closer
to our goal of becoming the global specialist in the treatment of
osteoarticular diseases in pets. We have strengthened our
management team as well as our Board of Directors to further our
commercial and strategic development. The promising clinical
results of VISCO-VET® in canine osteoarthritis hold up the promise
of becoming a reference treatment for all dogs suffering from
osteoarthritis. Finally, we are pursuing our BIOCERA-VET®
development strategy with determination, with commercial launches
in France and the Netherlands, as well as major distribution and
research agreements. As you can see, 2022 is opening with the same
momentum as last year, backed by a strong growth.”
Key events of the period
Positive safety and efficacy results for VISCO-VET® in canine
osteoarthritis
On September 8, 2021, the company announced positive
safety and efficacy results from its proof-of-concept clinical
study evaluating VISCO-VET® in canine osteoarthritis. A single
intra-articular injection of VISCO-VET® provided:
- A statistically significant improvement in dog’s mobility
- A statistically significant reduction in dog’s
osteoarthritis-related pain
- Long-lasting effects, and increasing over time, for up to 3
months after the injection
- Well tolerated with no adverse event reported
VISCO-VET®, the first product in its class with an effect
extended to 3 months following a single intra-articular injection,
targets a market of over 33 million dogs in Europe and the United
States.
Launch of the European multicentric clinical study of
VISCO-VET® in canine osteoarthritis
On September 10, 2021, the company announced the launch
of the European multicentric clinical study evaluating
VISCO-VET® in canine osteoarthritis in France and the
Netherlands. Patient enrolment started in October 2021.
Commercial launch of BIOCERA-VET® in France and The
Netherlands
On October 21, 2021, the company announced the launch and
first sales registered in these countries. This new milestone
propelled TheraVet into a market of over 25 million pets (cats and
dogs).
First patients treated with the BIOCERA-VET® Bone Surgery in
the United States of America
On October 26, 2021, the company announced the treatment
of the first patients in the United States, thereby marking the
launch of TheraVet's clinical case study with its BIOCERA-VET® bone
substitute in the US. The objective of the study, to be conducted
in a minimum of thirty (30) patients, is to collect additional data
on the safety and efficacy of BIOCERA-VET® for surgical procedures
such as arthrodesis, osteotomy, fracture and Tibial Tuberosity
Advancement (TTA).
Positive safety and efficacy results for BIOCERA-VET® in
canine osteosarcoma
On November 15, 2021, the company announced positive
safety and efficacy results of BIOCERA-VET®-OSA used in
cementoplasty as palliative treatment for canine osteosarcoma:
- Improvement of quality of life;
- Reduced pain for up to 6 months after the
surgery; and
- Low complication rate.
Cementoplasty using BIOCERA-VET®-OSA is a simple, minimally
invasive surgical procedure that is currently the only palliative
option for this very aggressive disease which affects ~30,000 dogs
per year in Europe and the United States.
Significant broad of the BIOCERA-VET® product line through
major distribution and research agreements
On November 22, 2021, the company announced a partnership
expanding significantly TheraVet’s bone substitutes portfolio with
(i) 2 new exclusive and complementary bone graft lines, (ii)
3D-bioprinted bone endoprostheses for patient-tailored bone
grafting surgeries & (iii) development of novel generation
proprietary products.
Commercial launch of BIOCERA-VET® for canine osteosarcoma in
Belgium, France and the Netherlands
On December 9, 2021, the company announced the start of
commercialization of BIOCERA-VET®-OSA, a game changer in the
palliative management of bone cancer in companion animals.
Cementoplasty with BIOCERA-VET® spares the affected limb, provides
significant pain relief and improves the quality of life of dogs
with bone cancer.
Strengthening of corporate governance with the appointment of
3 new independent board members
On December 16, 2021, the company announced the
strengthening of its governance with two new independent co-opted
directors, Simon Wheeler and Nesva Goris, and one independent
observer, Christian Schirvel.
Cash flow update as at 31 December 2021
Available cash at 31 December 2021 was €5.63m compared to €2.17m
at 31 December 2020, mainly due to the success of the €7.05m
capital increase in connection with the initial public offering on
Euronext Growth® Paris and Brussels.
About TheraVet SA
TheraVet is a veterinary biotechnology company specialising in
osteoarticular treatments for animals. The Company develops
targeted, safe and effective treatments to improve the quality of
life of pets suffering from osteoarticular diseases. For pet
owners, the health of their pets is a major concern and TheraVet’s
mission is to address the need for innovative and curative
treatments. TheraVet works closely with international opinion
leaders in order to provide a more effective response to
ever-growing needs in the field of veterinary medicine. TheraVet is
listed on Euronext Growth® Paris et Brussels, its head office is in
Gosselies, Belgium, and it has a subsidiary in the US.
For more information, visit the TheraVet website or follow us on
LinkedIn / Facebook / Twitter
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220124005653/en/
TheraVet Sabrina Ena Chief Operating Officer
sabrina.ena@thera.vet Tel: +32 71 96 00 43 Julie Winand Chief
Corporate Officer julie.winand@thera.vet
NewCap Investor Relations and Financial Communications
Théo Martin / Olivier Bricaud theravet@newcap.eu Tel: +33 1 44 71
94 94 Press Relations Arthur Rouillé / Ambre Delval
theravet@newcap.eu Tel: +33 1 44 71 00 15
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
